Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2018	View \| Download
Durvalumab in combination with Tremelimumab and Standard of Care Chemotherapy for EGFR Negative, ALK Negative Metastatic NSCLC– First Line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Durvalumab in combination with Tremelimumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Head and neck cancer	Head and Neck Cancer	2018	View \| Download
Edaravone for amyotrophic lateral sclerosis	Edaravone (IV) (Radicava; MCI-186; Radicut; Edaravone)	Motor neurone disease (MND or ALS)	Neurology	2018	View \| Download
Eflornithine in combination with Sulindac for Familial Adenomatus Polyposis	Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , Sulindac	Familial adenomatous polyposis (FAP)	Gastroenterology , Genetic Disorders	2018	View \| Download
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line	Dexamethasone (dexamethasone sodium metasulfobenzoate) , Elotuzumab (Empliciti; BMS-901608; HuLuc63) , Pomalidomide (Imnovid; CC-4047; Pomalyst)	Multiple myeloma (MM)	Haematological Cancer and Lymphomas	2018	View \| Download
Emapalumab for Primary Haemophagocytic Lymphohistiocytosis	Emapalumab (NI-0501; Gamifant)	Primary haemophagocytic lymphohistiocytosis (HLH)	Genetic Disorders , Immunology	2018	View \| Download
Enasidenib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an Isocitrate Dehydrogenase 2 (IDH2) Mutation	Enasidenib (Idhifa; AG-221; CC-90007)	Acute myeloid leukaemia (AML)	Haematological Cancer and Lymphomas	2018	View \| Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer	Entrectinib (RXDX-101)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients	Entrectinib (RXDX-101)	Solid tumours	Haematological Cancer and Lymphomas , Oncology	2018	View \| Download